Dr Lynda Corrigan (Tallaght University Hospital, Dublin, Ireland) and Dr Stephen Finn (The University of Dublin, Dublin, Ireland) discuss best practices for BRCA mutation testing in advanced prostate cancer, highlighting the importance of selecting appropriate samples and ensuring strong collaboration between clinicians and pathologists.

Key topics in this discussion include the differences between germline and somatic testing, optimal tissue selection, and the challenges of sample quality, storage, and tumour cellularity. The role of liquid biopsy (ctDNA) is explored as a complementary tool when tissue is unavailable, along with its limitations such as false negatives and clonal haematopoiesis.

The speakers emphasise that while tissue testing remains the preferred approach, liquid biopsy can provide valuable insights, particularly at disease progression. Multidisciplinary teamwork and careful interpretation of results are essential to ensure accurate diagnosis and guide treatment decisions.

To watch the other videos in this series click here.